After topping up its coffers last week, Symphogen A/S now has the cash and long-term investor base to see the Danish antibody platform play through its goal of building out a pipeline and taking at least one product to market.

The company secured €41 million ($53.4 million) in an extension of a tranched series E round co-led by existing investors Novo A/S and Danish pension fund PKA.